Optimi Health has secured an exclusive supply agreement with Mind Medicine Australia for MDMA and psilocybin.


This agreement will ensure Australian psychiatrists and researchers have affordable access to GMP grade medicines for clinical trials and the TGA’s Authorised Prescriber Scheme, which begins from July 1, 2023.

Read our press release for more details here.

Registered health professionals and researchers in Australia can fill out the EOI form below, and a member of our team will reach out to provide further details.

Send Inquiries Here